摘要
人们在过去的岁月中做出大量的努力去寻找阿尔茨海默病的潜在生物标记物,阿尔茨海默病由轻度认知障碍进展(被认为是一种由正常老化发展成为阿尔茨海默病的中间相)而来。然而,我们任然大量缺乏引起疾病的致病机制。在本研究中,我们应用基于超高效液相色谱-质谱法的血清代谢物组学来研究不同课题(阿尔茨海默病组,轻度认知障碍组和健康对照)之间的代谢差别。最重要的发现与磷脂和鞘脂的代谢损伤导致膜破裂有关,其中似乎有酰基链长度和不饱和度结构的脂肪酸起着至关重要的作用。此外,一些关于阿尔茨海默病已知致病过程的判别代谢物被首次发现,如有关于线粒体功能障碍的酰基肉碱的累积,内源性大麻系统缺陷导致的油酸酰胺和单甘脂水平的降低或者血清苯乙酰谷氨酰胺的增加可能会揭示谷氨酰胺稳态的改变。因此,这些结果代表了一个合适的概况来了解此病的致病机理和进程。
关键词: 阿尔茨海默病,疾病进展,膜破裂,代谢物组学,轻度认知障碍,致病机理
Current Alzheimer Research
Title:Metabolomic-Driven Elucidation of Serum Disturbances Associated with Alzheimer's Disease and Mild Cognitive Impairment
Volume: 13 Issue: 6
Author(s): Raúl González-Domínguez, Francisco Javier Rupérez, Tamara García-Barrera, Coral Barbas, José Luis Gómez-Ariza
Affiliation:
关键词: 阿尔茨海默病,疾病进展,膜破裂,代谢物组学,轻度认知障碍,致病机理
摘要: Numerous efforts have been made in the last years to discover potential biomarkers of Alzheimer’s disease and its progression from mild cognitive impairment, considered as an intermediate phase in the development of Alzheimer’s disease from normal aging. However, there is still a considerable lack of understanding about pathological mechanisms underlying to disease. In the present study, serum metabolomics based on ultra-high-performance liquid chromatographymass spectrometry was applied to investigate metabolic differences between subjects with Alzheimer’s disease and mild cognitive impairment, as well as healthy controls. The most important findings can be associated with impaired metabolism of phospholipids and sphingolipids leading to membrane breakdown, wherein the nature of the fatty acids contained in the structure in terms of acyl chain length and degree of unsaturation appears to play a crucial role. Furthermore, several discriminant metabolites were found for the first time in relation to known pathological processes associated with Alzheimer’s disease, such as the accumulation of acylcarnitines in relation to mitochondrial dysfunction, decreased levels of oleamide and monoglycerides as a result of defects in endocannabinoid system, or increased serum phenylacetylglutamine, which could reveal alterations in glutamine homeostasis. Therefore, these results represent a suitable approximation to understand the pathogenesis and progression of the disease.
Export Options
About this article
Cite this article as:
Raúl González-Domínguez, Francisco Javier Rupérez, Tamara García-Barrera, Coral Barbas, José Luis Gómez-Ariza , Metabolomic-Driven Elucidation of Serum Disturbances Associated with Alzheimer's Disease and Mild Cognitive Impairment, Current Alzheimer Research 2016; 13 (6) . https://dx.doi.org/10.2174/1567205013666160129095138
DOI https://dx.doi.org/10.2174/1567205013666160129095138 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of Annexin A1 and Formyl Peptide Receptor 2/3 Signaling in Chronic Corticosterone-Induced Depression-Like behaviors and Impairment in Hippocampal-Dependent Memory
CNS & Neurological Disorders - Drug Targets Enhanced Risk for Specific Somatic Myeloproliferative Neoplastic Mutations in Patients with Stroke
Current Neurovascular Research Pharmacologic Strategies for Suppression of Lipid Peroxidation in Neurodegeneration
Current Neuropharmacology Patient Involvement and Shared Decision-Making in Mental Health Care
Current Clinical Pharmacology “Tripping out” with the TRP Superfamily and TRPV1 for Novel Neuroprotection
Current Neurovascular Research Cross Currents in Protein Misfolding Disorders: Interactions and Therapy
CNS & Neurological Disorders - Drug Targets “Virostatics” as a Potential New Class of HIV Drugs
Current Pharmaceutical Design Preface [Hot topic: Current Pharmacotherapeutic Approaches to the Treatment of Cognitive Impairment in Alzheimers Disease and Related Disorders (Executive Editor : Bernd Ibach)]
Current Pharmaceutical Design Cardiovascular Risk Factors in Chronic Inflammatory Rheumatic Diseases: Modern Assessment and Diagnosis
Current Vascular Pharmacology Pharmacological Interventions to Attenuate Alzheimer’s Disease Progression: The Story So Far
Current Alzheimer Research GSK-3 Inhibitors: Recent Developments and Therapeutic Potential
Current Signal Transduction Therapy Urinary Albumin to Creatinine Ratio as Potential Biomarker for Cerebral Microvascular Disease
Current Neurovascular Research A Case of Ischemic Stroke in Acute Promyelocytic Leukemia at Initial Presentation: Relevance of All-Trans Retinoic Acid Treatment
Cardiovascular & Hematological Disorders-Drug Targets Pleiotropic Effect of Statins as Antioxidants on Cardiac Hypertrophy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Role of Genes (and Environmental Stress) in Depression: An Update
Current Psychiatry Reviews Stroke Prevention: From Available Antiplatelet Drugs to Novel Molecular Targets
Current Drug Targets Micro-RNA in Disease and Gene Therapy
Current Drug Discovery Technologies Alzheimer’s and Type 2 Diabetes Treatment via Common Enzyme Targeting
CNS & Neurological Disorders - Drug Targets Zederone Improves the Fecal Microbial Profile in Dementia Induced Rat Model: A First Report
CNS & Neurological Disorders - Drug Targets DYRK1A Kinase Inhibitors with Emphasis on Cancer
Mini-Reviews in Medicinal Chemistry